Alkermes Net Income 2006-2021 | ALKS

Alkermes net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Alkermes Annual Net Income
(Millions of US $)
2020 $-111
2019 $-197
2018 $-139
2017 $-158
2016 $-208
2015 $-227
2014 $-30
2013 $18
2013 $25
2012 $-114
2011 $-46
2010 $-40
2009 $131
2008 $167
2007 $9
2006 $4
2005 $-75
Alkermes Quarterly Net Income
(Millions of US $)
2021-09-30 $-29
2021-06-30 $2
2021-03-31 $-22
2020-12-31 $-43
2020-09-30 $-0
2020-06-30 $-29
2020-03-31 $-39
2019-12-31 $-5
2019-09-30 $-53
2019-06-30 $-42
2019-03-31 $-96
2018-12-31 $-10
2018-09-30 $-34
2018-06-30 $-33
2018-03-31 $-63
2017-12-31 $-10
2017-09-30 $-36
2017-06-30 $-43
2017-03-31 $-69
2016-12-31 $-21
2016-09-30 $-63
2016-06-30 $-47
2016-03-31 $-77
2015-12-31 $-69
2015-09-30 $-81
2015-06-30 $-46
2015-03-31 $-31
2014-12-31 $31
2014-09-30 $-40
2014-06-30 $4
2014-03-31 $-24
2013-12-31 $18
2013-09-30 $-8
2013-06-30 $7
2013-03-31 $3
2012-12-31 $16
2012-09-30 $-17
2012-06-30 $22
2012-03-31 $-63
2011-12-31 $-15
2011-09-30 $-22
2011-06-30 $-13
2011-03-31
2010-12-31 $-11
2010-09-30 $-8
2010-06-30 $-13
2010-03-31
2009-12-31 $-7
2009-09-30 $-9
2009-06-30 $-10
2009-03-31
2008-12-31 $113
2008-09-30 $2
2008-06-30 $30
2008-03-31
2007-12-31 $169
2007-09-30 $8
2007-06-30 $9
2007-03-31
2006-12-31 $3
2006-09-30 $4
2006-06-30 $-1
2006-03-31
2005-12-31 $1
2005-09-30 $12
2005-06-30 $-14
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.564B $1.039B
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90